RIG
ABMD

RiverFront Investment Group’s Abiomed Inc ABMD Stock Holding History

RiverFront Investment Group’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-957
Closed -$299K – 140
2021
Q2 		$299K Buy
957
+248
+35% +$76.1K 0.01% 88
2021
Q1 		$226K Sell
709
-63
-8% -$20.2K ﹤0.01% 114
2020
Q4 		$250K Buy
+772
New +$214K 0.01% 76

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

RiverFront Investment Group's ABMD Position: Q3 2021 in Review

RiverFront Investment Group sold out of Abiomed Inc (ABMD) in Q3 2021, closing a stake of 957 shares — an estimated $299K sold.

RiverFront Investment Group first reported a position in ABMD in Q4 2020 and held it in 3 quarters. The position peaked at $299K in Q2 2021. 498 funds tracked by Wall St. Rank hold ABMD as of Q3 2021.

  • RiverFront Investment Group reported no remaining Abiomed Inc position as of Q3 2021 after selling out during the quarter.
  • RiverFront Investment Group sold 957 Abiomed Inc shares in Q3 2021, an estimated $299K.
  • RiverFront Investment Group first reported a position in Abiomed Inc in Q4 2020 and held it in 3 quarters.
  • RiverFront Investment Group's Abiomed Inc position peaked at $299K in Q2 2021.
  • 498 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2021.

Based on RiverFront Investment Group's 13F filing for Q3 2021, filed 2 Nov 2021.